


AZD3759 hydrochloride

Chemical Properties

CAS No. :	1626387-81-2
Formula:	C ₂₂ H ₂₄ Cl ₂ FN ₅ O ₃
Molecular Weight:	496.36
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	AZD3759 (hydrochloride) is an effective, orally active and central nervous system-penetrant EGFR inhibitor. At Km ATP concentrations, the IC ₅₀ s are 0.2/0.3/0.2 nM for EGFR (L858R)/EGFR (wt)/EGFR (exon 19Del).
Targets(IC ₅₀)	Apoptosis,EGFR
In vitro	At 2 mM of ATP concentrations, the IC ₅₀ s are 102/7.6/2.4 nM for EGFR (wt)/EGFR (L858R) /EGFR (exon 19Del). AZD3759 also inhibits pEGFR in H838wt (IC ₅₀ : 64.5 nM), H3255L858R (IC ₅₀ : 7.2 nM), and PC-9exon 19Del (IC ₅₀ : 7.4 nM), respectively. In cellular phosphorylation studies, AZD3759 also shows 9-fold inhibition selectivity in EGFR-activating mutant cell lines over EGFR wild-type cell lines (H838 cell line)[1].
In vivo	In rats, absorption of AZD3759 (2 mg/kg, p.o.) is rapid with blood C _{max} of 0.58 μM achieved at 1.0 h. And then blood concentrations of AZD3759 decline monoexponentially with a mean elimination half-life of 4.3 h, which is close to the parameter obtained from intravenous dosing of 4.1 h. The bioavailability following an oral dose in rats is 91%. Following the intravenous in dogs, the blood clearance of AZD3759 is 14 mL/min/kg, and the volume of distribution is 6.4 L/kg. Its elimination half-life is 6.2 h. Absorption of AZD3759 is rapid with blood C _{max} (698 nM) occurring between 0.5 and 1.5 h. The oral bioavailability of AZD3759 is excellent at 90%. AZD3759 demonstrated significant dose-dependent antitumor efficacy (78% tumor growth inhibition at 7.5 mg/kg/day and tumor regression at 15 mg/kg/day, respectively, 4 weeks after treatment) with <20% body weight loss. AZD3759 (7.5/15 mg/kg) can markedly decrease tumor area. In addition, modulation of pEGFR is detected by a single dose of AZD3759 at 15 mg/kg 1h after dosing[1].
Kinase Assay	AZD3759 is tested at a single 1 μM concentration across each of 124 kinases from Millipore kinase panel at an ATP concentration that is within 15 μM of their corresponding apparent Km values. In brief, recombinant kinases are incubated within an appropriate buffer containing peptide substrate and radiolabelled γ-33P-ATP together with presence or absence of required inhibitor concentration. The reaction is initiated by adding ATP/Mg ²⁺ mix. After incubation for 40 minutes at room temperature, the reaction is stopped by adding 3% phosphoric acid solution. A portion of reaction mix is spotted onto P30 filter mat to trap peptide and washed three times for 5 minutes with phosphoric acid to remove non-specific γ-33P-ATP. The phosphorylated substrate is then measured by scintillation counting, which determined the level of kinase activity inhibition compared to control reactions[1].

Cell Research	AZD3759 is prepared in DMSO and stored, and then diluted with the appropriate medium before use[1]. Cell proliferation assay is determined by MTS methods. Briefly, cells are seeded in 96-well plates (at a density to allow for logarithmic growth during the 72-hour assay) and incubated overnight at 37°C and 5% CO ₂ . Cells are then exposed to concentrations of compounds (e.g., AZD3759) ranging from 30 mM to 0.3 μM for 72 hours. For the MTS endpoint, cell proliferation is measured by the CellTiter Aqueous Non-Radioactive Cell Proliferation Assay reagent. Absorbance is measured with a Tecan Ultra instrument. Predose measurements are made, and concentration needed to reduce the growth of treated cells to half that of untreated cells (GI ₅₀) values are determined using absorbance readings[1].
Animal Research	AZD3759 is prepared in 1% methylcellulose (Rat)[1]. Male Han Wistar rats are orally dosed with the AZD3759 at 2 mg/kg in 1% methylcellulose. At 0.25, 0.5, 1, 2, 4 and 7 hour post-dose, cerebral spinal fluid (CSF) is collected from cisterna magna, and blood samples (>60 μL/time point/each site) are collected via cardiac puncture, into separate EDTA coagulated tubes, and then immediately diluted with 3-fold volume of water. Brain tissue is harvested and homogenized in 3x volume of 100 mM phosphate buffered saline (pH7.4). All samples are stored at -70°C prior to LC/MS/MS analysis.

Solubility Information

Solubility	DMSO: 50 mg/mL (100.73 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0147 mL	10.0733 mL	20.1467 mL
5 mM	0.4029 mL	2.0147 mL	4.0293 mL
10 mM	0.2015 mL	1.0073 mL	2.0147 mL
50 mM	0.0403 mL	0.2015 mL	0.4029 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Zeng Q, et al. Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. J Med Chem. 2015 Oct 22;58(20): 8200-15.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481